pioglitazone has been researched along with Substance Withdrawal Syndrome in 9 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Substance Withdrawal Syndrome: Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We showed that activation of PPARγ receptors by pioglitazone (0, 10, and 30 mg/kg) and rosiglitazone (0, 10 and 30 mg/kg) given orally selectively reduced alcohol drinking." | 7.77 | Activation of nuclear PPARγ receptors by the antidiabetic agent pioglitazone suppresses alcohol drinking and relapse to alcohol seeking. ( Braconi, S; Cannella, N; Ciccocioppo, R; Cippitelli, A; Demopulos, G; Gaitanaris, G; Heilig, M; Kallupi, M; Massi, M; Ruggeri, B; Somaini, L; Stopponi, S, 2011) |
| "We showed that activation of PPARγ receptors by pioglitazone (0, 10, and 30 mg/kg) and rosiglitazone (0, 10 and 30 mg/kg) given orally selectively reduced alcohol drinking." | 3.77 | Activation of nuclear PPARγ receptors by the antidiabetic agent pioglitazone suppresses alcohol drinking and relapse to alcohol seeking. ( Braconi, S; Cannella, N; Ciccocioppo, R; Cippitelli, A; Demopulos, G; Gaitanaris, G; Heilig, M; Kallupi, M; Massi, M; Ruggeri, B; Somaini, L; Stopponi, S, 2011) |
| "Naloxone was administrated 2 h after the morphine last dose, and withdrawal symptoms were recorded for 45 min." | 1.40 | Pioglitazone prevents morphine antinociception tolerance and withdrawal symptoms in rats. ( Azarfardian, A; Charkhpour, M; Ghasami, S; Ghavimi, H; Hassanzadeh, K; Maleki-Dizaji, N; Zolali, E, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Domi, E | 1 |
| Caputi, FF | 1 |
| Romualdi, P | 1 |
| Domi, A | 1 |
| Scuppa, G | 2 |
| Candeletti, S | 1 |
| Atkins, A | 1 |
| Heilig, M | 3 |
| Demopulos, G | 3 |
| Gaitanaris, G | 3 |
| Ciccocioppo, R | 3 |
| Ubaldi, M | 1 |
| Pariente, A | 1 |
| Mansiaux, Y | 1 |
| Jarné, A | 1 |
| Salvo, F | 1 |
| Pageot, C | 1 |
| Bezin, J | 1 |
| Smith, A | 1 |
| Bégaud, B | 1 |
| Schroeder, JR | 1 |
| Phillips, KA | 1 |
| Epstein, DH | 1 |
| Jobes, ML | 1 |
| Furnari, MA | 1 |
| Kennedy, AP | 1 |
| Preston, KL | 1 |
| Ghavimi, H | 2 |
| Azarfardian, A | 2 |
| Maleki-Dizaji, N | 2 |
| Hassanzadeh, K | 2 |
| Ghanbarzadeh, S | 1 |
| Charkhpour, M | 2 |
| Ghasami, S | 1 |
| Zolali, E | 1 |
| Tripathy, D | 1 |
| Schwenke, DC | 1 |
| Banerji, M | 1 |
| Bray, GA | 1 |
| Buchanan, TA | 1 |
| Clement, SC | 1 |
| Henry, RR | 1 |
| Kitabchi, AE | 1 |
| Mudaliar, S | 1 |
| Ratner, RE | 1 |
| Stentz, FB | 1 |
| Musi, N | 1 |
| Reaven, PD | 1 |
| DeFronzo, RA | 1 |
| de Guglielmo, G | 1 |
| Kallupi, M | 2 |
| Stopponi, S | 1 |
| Somaini, L | 1 |
| Cippitelli, A | 1 |
| Cannella, N | 1 |
| Braconi, S | 1 |
| Ruggeri, B | 1 |
| Massi, M | 1 |
| Javadi, S | 1 |
| Ejtemaeimehr, S | 1 |
| Keyvanfar, HR | 1 |
| Moghaddas, P | 1 |
| Aminian, A | 1 |
| Rajabzadeh, A | 1 |
| Mani, AR | 1 |
| Dehpour, AR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pioglitazone as an Aid During Buprenorphine Taper[NCT01517165] | Phase 1 | 24 participants (Actual) | Interventional | 2012-01-04 | Terminated | ||
| Actos Now for Prevention of Diabetes (ACT NOW)[NCT00220961] | Phase 3 | 602 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Fasting Plasma Glucose (NCT00220961)
Timeframe: Baseline versus 2.4 years
| Intervention | mg/dl (Mean) |
|---|---|
| Placebo | -4.0 |
| Pioglitazone | -10.7 |
Insulin sensitivity The Matsuda index was calculated as 10,000/square root of (pre-meal glucose x pre-meal insulin x mean 120 min post-meal glucose x mean 120 min post-meal insulin), with higher numbers indicating better the insulin sensitivity. (NCT00220961)
Timeframe: Baseline versus 2.4 years
| Intervention | matsuda index (Mean) |
|---|---|
| Placebo | 0.7 |
| Pioglitazone | 3.6 |
Insulin secretion (NCT00220961)
Timeframe: Baseline versus 2.4 years
| Intervention | nmol (Mean) |
|---|---|
| Placebo | 35 |
| Pioglitazone | 25 |
carotid intima thickness (NCT00220961)
Timeframe: Baseline versus 2.4 years
| Intervention | percentage of intima (Mean) |
|---|---|
| Placebo | 1.7 |
| Pioglitazone | 3.2 |
Percentage of Participants with Type 2 Diabetes at 2.4 years Post-randomization (NCT00220961)
Timeframe: 2.4 years
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 16.1 |
| Pioglitazone | 5.0 |
1 trial available for pioglitazone and Substance Withdrawal Syndrome
| Article | Year |
|---|---|
Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Cytokines; Double-Blind Method; Female; Humans; Male; Midd | 2018 |
8 other studies available for pioglitazone and Substance Withdrawal Syndrome
| Article | Year |
|---|---|
Activation of PPARγ Attenuates the Expression of Physical and Affective Nicotine Withdrawal Symptoms through Mechanisms Involving Amygdala and Hippocampus Neurotransmission.
Topics: Affect; Amygdala; Anilides; Animals; Anxiety; Behavior, Animal; gamma-Aminobutyric Acid; Hippocampus | 2019 |
Impact of pioglitazone regulatory withdrawal on antidiabetic drug use and health in diabetic patients.
Topics: Diabetes Mellitus; Hospitalization; Humans; Hypoglycemic Agents; Pioglitazone; Substance Withdrawal | 2017 |
Acute administration of pioglitazone attenuates morphine withdrawal syndrome in rat: a novel role of pioglitazone.
Topics: Analgesics, Opioid; Anilides; Animals; Male; Morphine; Morphine Dependence; Naloxone; Pioglitazone; | 2015 |
Pioglitazone prevents morphine antinociception tolerance and withdrawal symptoms in rats.
Topics: Analgesics, Opioid; Anilides; Animals; Behavior, Animal; Drug Tolerance; Male; Morphine; Motor Activ | 2014 |
Diabetes Incidence and Glucose Tolerance after Termination of Pioglitazone Therapy: Results from ACT NOW.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incidence; Insulin; I | 2016 |
Pioglitazone attenuates the opioid withdrawal and vulnerability to relapse to heroin seeking in rodents.
Topics: Analgesics, Opioid; Animals; Behavior, Addictive; Conditioning, Operant; Heroin; Male; Mice; Morphin | 2017 |
Activation of nuclear PPARγ receptors by the antidiabetic agent pioglitazone suppresses alcohol drinking and relapse to alcohol seeking.
Topics: Adrenergic alpha-2 Receptor Antagonists; Alcohol Drinking; Alcohols; Analysis of Variance; Anilides; | 2011 |
Pioglitazone potentiates development of morphine-dependence in mice: possible role of NO/cGMP pathway.
Topics: Animals; Cell Line, Tumor; Cyclic AMP; Cyclic GMP; Disease Models, Animal; Enzyme Inhibitors; Gliobl | 2013 |